Spyre Therapeutics Balance Sheet
NASDAQ: SYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Spyre Therapeutics financial position
At the end of fiscal 2025, Spyre Therapeutics reported total assets of $777.8 million, up 27.8% from a year earlier against total liabilities of $62.5 million. Shareholders' equity stood at $715.2 million, or 92.0% of assets. The company held $85.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 13.25, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Spyre Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 85.72M | 89.42M | 188.89M | 34.86M | 15.14M | 90.09M | 19.25M | 22.46M | 12.82M | 47.75M |
| Short-Term Investments | 670.81M | 513.66M | 150.38M | 20.85M | 77.99M | 56.18M | 52.70M | 52.05M | 37.48M | 15.75M |
| Total Current Assets | 777.78M | 608.47M | 341.53M | 62.26M | 98.89M | 149.79M | 74.50M | 76.67M | 54.99M | 66.42M |
| Property, Plant & Equipment | — | — | 0 | 3.22M | 4.55M | 5.64M | 2.38M | 1.02M | 854.00K | 599.00K |
| Total Assets | 777.78M | 608.48M | 341.86M | 71.14M | 109.93M | 161.62M | 83.18M | 77.74M | 56.08M | 67.06M |
| Accounts Payable | — | — | 896.00K | 677.00K | 3.32M | 2.25M | 3.15M | 663.00K | 389.00K | 168.00K |
| Total Current Liabilities | 58.69M | 54.06M | 31.98M | 14.66M | 20.14M | 16.44M | 18.36M | 10.24M | 5.63M | 3.96M |
| Total Liabilities | 62.55M | 90.68M | 73.29M | 20.84M | 25.98M | 21.79M | 23.10M | 10.31M | 5.74M | 4.10M |
| Shareholders' Equity | 715.24M | 517.80M | 184.02M | 50.30M | 83.94M | 139.83M | 60.08M | 67.43M | 50.34M | 62.97M |
| Retained Earnings | -1.13B | -972.43M | -764.41M | -425.62M | -341.81M | -276.01M | -195.12M | -116.86M | -72.51M | -45.28M |
| Net Cash (Debt) | 756.53M | 603.09M | 339.28M | 55.71M | 93.13M | 146.27M | 71.95M | 74.51M | 50.30M | 63.50M |
| Shares Outstanding | 78.19M | 60.26M | 36.06M | 2.61M | 49.36M | 47.96M | 29.08M | 24.14M | 16.67M | 13.43M |
This table shows 10 annual periods of Spyre Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow SYRE's reporting calendar. What is a balance sheet?